StockWatch
·

AtriCure, Inc. Q1 FY26 Results

ATRCQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue141.2514.3%
Total Income141.2514.3%
Expenditure140.728.6%
PBT0.39106.0%
Net Profit0.11101.6%
OPM0.37%5.19pp
NPM0.08%5.53pp
EPS0.00100.0%
View full financials

AtriCure Reports First Quarter 2026 Revenue of $141.2 Million, Up 14.3% YOY

06 May 2026 · 6 May, 1:33 am

Summary

AtriCure reported a 14.3% increase in worldwide revenue for the first quarter of 2026, reaching $141.2 million. U.S. revenue grew by 14.9% to $116.2 million, driven by sales of cryoSPHERE® MAX™, AtriClip FLEX-Mini®, AtriClip PRO-Mini®, and EnCompass® clamp. Adjusted EBITDA increased by 95% to $17.1 million. The company projects full year 2026 revenue to be approximately $600 million to $610 million and adjusted EBITDA of approximately $80 million to $82 million.

Key Highlights

  1. 1

    AtriCure's worldwide revenue for the first quarter of 2026 reached $141.2 million, reflecting a 14.3% increase compared to the first quarter of 2025.

  2. 2

    U.S. revenue for the first quarter of 2026 was $116.2 million, representing a 14.9% increase compared to the first quarter of 2025.

  3. 3

    International revenue increased by 11.5% to $25.0 million in the first quarter of 2026.

  4. 4

    Gross profit for the first quarter of 2026 was $109.3 million, compared to $92.6 million for the first quarter of 2025.

  5. 5

    Gross margin improved to 77.4% for the first quarter of 2026, an increase of 246 basis points from the first quarter of 2025.

  6. 6

    Adjusted EBITDA for the first quarter of 2026 was $17.1 million, a 95% increase from the first quarter of 2025.

  7. 7

    The company projects full year 2026 revenue to be approximately $600 million to $610 million and adjusted EBITDA of approximately $80 million to $82 million.

Management Comments

M

Michael Carrel

“Our first quarter results reflect the durability of AtriCure’s growth model, fueled by disciplined execution and increased adoption of our innovative products." “Strong revenue growth, combined with improving profitability and meaningful advancement across our clinical initiatives, gives us confidence that we are building a foundation to drive the next era of growth and value creation for AtriCure and our shareholders.”

Informational and educational content only. Not investment advice.